Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words eight years ago from the mother of a child with Fanconi anemia (FA).

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the ...

Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment ...

Recent health updates see UnitedHealth shareholders challenging healthcare denial impacts. BRCA2 cancer gene mutation risks ...

Recent studies have identified risks in BRCA2 gene mutations, leading to better cancer risk assessment and treatment. Other ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer.

Patients with a form of breast cancer in England will be offered a new treatment after it was given the green light for NHS ...

A landmark study overturns common beliefs about breast cancer surgery, revealing new insights into treatment choices and ...

Breast Cancer Now said olaparib will be an ‘valuable alternative’ for patients with a certain type of secondary breast cancer.

Bad memory? Poor sleep habits? These inherited traits may come from your parents. But who's to blame? Here's what the science ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.